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With reduced prevalence of visceral leishmaniasis (VL) in the Indian subcontinent (ISC),
direct and field deployable diagnostic tests are needed to implement an effective
diagnostic and surveillance algorithm for post-elimination VL control. In this regard, here
we investigated the diagnostic efficacies of a loop-mediated isothermal amplification
(LAMP) assay (Loopamp™ Leishmania Detection Kit, Eiken Chemical CO., Ltd, Japan), a
real-time quantitative PCR assay (qPCR) and the Leishmania antigen ELISA (CLIN-TECH,
UK) with different sampling techniques and evaluated their prospect to incorporate into
post-elimination VL control strategies. Eighty clinically and rK39 rapid diagnostic test
confirmed VL cases and 80 endemic healthy controls were enrolled in the study.
Peripheral blood and dried blood spots (DBS) were collected from all the participants at
the time of diagnosis. DNA was extracted from whole blood (WB) and DBS via silica
columns (QIAGEN) and boil & spin (B&S) methods and tested with qPCR and Loopamp.
Urine was collected from all participants at the time of diagnosis and was directly
subjected to the Leishmania antigen ELISA. 41 patients were followed up and urine
samples were collected at day 30 and day 180 after treatment and ELISA was performed.
The sensitivities of the Loopamp-WB(B&S) and Loopamp-WB(QIA) were 96.2% (95% CI
89·43-99·22) and 95% (95% CI 87·69-98·62) respectively. The sensitivity of Loopamp-
DBS(QIA) was 85% (95% CI 75·26- 92·00). The sensitivities of the qPCR-WB(QIA) and
qPCR-DBS(QIA) were 93.8% (95% CI 86·01-97·94) and 72.5% (95% CI 61·38-81·90)gy | www.frontiersin.org April 2021 | Volume 11 | Article 6707591
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Frontiers in Cellular and Infection Microbiolorespectively. The specificity of all molecular assays was 100%. The sensitivity and
specificity of the Leishmania antigen ELISA were 97.5% (95% CI 91·47-99·70) and
91.95% (95% CI 84·12-96·70) respectively. The Leishmania antigen ELISA depicted
clinical cure at day 180 in all the followed-up cases. Efficacy and sustainability identify the
Loopamp-WB(B&S) and the Leishmania antigen ELISA as promising and minimally
invasive VL diagnostic tools to support VL diagnostic and surveillance activities
respectively in the post-elimination era.Keywords: visceral leishmaniasis, diagnosis, LAMP, qPCR, urine ELISA, elimination, diagnostics for VL post-
elimination eraINTRODUCTION
Visceral leishmaniasis (VL), also known as kala-azar, is a vector-
borne parasitic disease caused by protozoans of the Leishmania
donovani complex, which are transmitted by phlebotomine
sandflies (Chappuis et al., 2007). On the Indian subcontinent
(ISC) the disease is caused by Leishmania donovani, which is
transmitted in an anthroponotic cycle and is responsible for
significant morbidity and mortality (Matlashewski et al., 2011).
For years, the estimated global VL incidence ranged between
50,000-90,000 cases per year (Bi et al., 2018), and three countries,
Bangladesh, India, and Nepal, contributed to 60-80% of the
reported incidences1. In 2005, the three countries signed a
memorandum of understanding and launched the kala-azar
elimination program on the ISC to eliminate VL as a public
health problem by 2015, later extended to 2020 (Selvapandiyan
et al., 2019). The program aimed to attain less than 1 case per
10,000 people at the intervention unit level in three phases:
achieving the target incidence in the attack phase, retaining the
incidence for 3 consecutive years in the consolidation phase, and
following validation by the World Health Organization (WHO),
sustaining the target incidence in the maintenance phase (Le
Rutte et al., 2018). Bangladesh and Nepal achieved the target in
2016 and 2013 respectively and wait for validation while
incidence is reduced below the target in the majority of
intervention units in India (Rijal et al., 2019). The attainment
of the target incidence led to a drastic reduction in the reported
case numbers in the three countries, from 41,158 in 2005 to 3,105
cases that contributed to a 77% decrease in global VL incidence
in 20191.
The reduction in VL prevalence on the ISC is attributed to the
policies and strategies taken by the elimination program in the
attack phase. Notably, the implementation of a point-of-care
diagnostic test, the rK39 rapid diagnostic test (RDT), and an
improved treatment regimen, single-dose liposomal
amphotericin B (LAmB) accelerated the progression of the
program (Olliaro et al., 2017). However, the program must re-
evaluate detection strategies and interventions for the post-
elimination era in accordance with a reduced VL prevalence.
While the rK39 RDT acted as a protagonist during the attack
phase, the assay is likely to lose its positive predictive value in thery, WHO, 2021. https://apps.who.int/
ccessed February 2021].
gy | www.frontiersin.org 2maintenance phase with fewer cases (Rijal et al., 2019) leading to
the incorrect treatment of non-VL cases. Moreover, the rK39
RDT is unsuitable as a test of cure and for diagnosis of relapse
cases due to the inability to differentiate past and new infection -
an inherent limitation of indirect diagnostic approaches
(Srividya et al., 2012). Furthermore, the existing diagnostic
algorithm includes visible disease manifestations for at least
two weeks (NKEP, CDC, 2016) which unfortunately extends
the period of infectiousness and transmissibility. Therefore, a
direct and field-deployable diagnostic method is crucial for
prompt management of sporadic cases and limit the
transmission in the post-elimination setting.
Despite sincere efforts, a sensitive, direct detection method that
circumvents the limitations of the rK39 RDT and is suitable for
peripheral settings remains unavailable. Molecular assays such as
real-time quantitative polymerase chain reaction (qPCR) are the
most sensitive direct detection methods; though, the high
maintenance and associated cost confined its application to
research relevant activities (Sundar and Singh, 2019). Persisting
efforts led to the development of different sensitive molecular assays
(e.g. Loop-mediated isothermal amplification-LAMP, recombinase
polymerase amplification-RPA) that eliminate the necessity for
expensive thermocyclers with shorter turnaround time, while
utilization of dried reagents substantially increased the prospect of
introducing the assays in near-patient settings (Mondal et al., 2016;
Nzelu et al., 2019; Rijal et al., 2019). However, template preparation
methods significantly influence the assay throughput and the
requirement of expensive and labor-intensive nucleic
acid extraction techniques often restrict such initiatives. Moreover,
diagnostic techniques accompanying safer and non- or minimally
invasive sampling methods are required to increase patient
compliance, especially for the low prevalence setting in the post-
elimination era.
In an endeavor to evaluate such direct diagnostic tools, in this
study, we determined the efficacies of a reference qPCR and a
LAMP assay (Loopamp™ Leishmania Detection Kit, Eiken Co.,
Ltd, Japan). The assay showed excellent efficacies in detecting VL
cases in Sudan and cutaneous leishmaniasis cases in Afghanistan
and Suriname previously (Mukhtar et al., 2018; Vink et al., 2018;
Schallig et al., 2019). Here, we performed the Loopamp assay with
whole blood and dried blood spots and evaluated the effect on the
diagnostic efficacies of two different extraction methods,
commercial silica-based spin-columns and an in-house boil &April 2021 | Volume 11 | Article 670759
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antigen ELISA (CLIN-TECH, UK) in urine samples, previously
showing promise in the detection of VL cases from Bangladesh
and Ethiopia in a pilot study (Vallur et al., 2015), as a non-invasive
diagnostic assay and test of treatment response over 6 months.METHODS AND MATERIALS
Ethics Statement
The study was conducted in accordance with the Declaration of
Helsinki and approved by the International Centre for Diarrheal
Disease Research, Bangladesh (icddr,b) ethical review committee
(PR-14093). Written informed consent was obtained from each
adult participant or guardian of any participant aged less than
18 years.
Study Sites and Participant
Characteristics
All study participants were enrolled from Mymensingh division,
a highly endemic region for VL that accounts for more than half
of the total VL patients in Bangladesh. Sample collection and
template preparation was performed at Surya Kanta Kala-azar
Research Center (SKKRC), Mymensingh. Laboratory tests were
performed at the icddr,b, Dhaka. All participants were enrolled
between June 2016 to March 2018. Clinical diagnosis of the
patients was performed according to the national guidelines of
Bangladesh (NKEP, CDC, 2016). Individuals without a history of
VL, suffering from a fever of more than two weeks in duration,
splenomegaly, and positive with rK39 rapid detection test (RDT)
were enrolled and defined as VL cases. Age and sex-matched
clinically healthy household contacts of VL cases with no history
of VL, or any symptoms of severe, acute, or chronic illness and a
negative rK39 RDT were enrolled as endemic healthy controls.
rK39 RDT was performed with serum sample of the suspected
cases showing clinical symptoms by Kala-azar Detect™ Rapid
Test kit according to the manufacturer’s instruction (Inbios
International, Inc., USA). A total of 80 VL patients and 80
endemic healthy controls were included in the study. The
admission, clinical management and treatment of patients was
arranged at SKKRC. All VL patients were treated with a single
dose intravenous infusion of 10 mg/kg LAmB, as per the national
guidelines. Patients were followed up at 6 months and 12 months
after treatment to monitor their response to treatment and
development of VL related post-treatment complications.
Clinical Specimens
Ten milliliters of whole blood and 50mL morning urine were
collected from all participants at baseline. Serum was separated
by centrifuging 3mL whole blood at a rate of 3,500 rpm for 5
minutes. Dried blood spots (DBS) were prepared by the addition
of 45µL whole blood to Whatman® FTA® cards (Sigma-
Aldrich). Urine was also collected from 41 VL patients at 30
and 180 days after completion of treatment. Cold chain (4°C)
maintenance was assured while transporting the samples to
icddr,b, for laboratory analysis.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Template Preparation by QIAGEN
Extraction Method
DNA was isolated from 200µL heparin treated whole blood
(WB-QIA) and three 5mm punched-out circles from a dried
blood spot (DBS-QIA) using a QIAamp DNA tissue and blood
mini kit (QIAGEN, Hilden, Germany). Extracted DNA was
eluted into 200mL and 150mL of elution buffer provided with
the kits respectively, as per the manufacturer’s instructions.
Extracted DNA samples were stored at –80°C.
Template Preparation by Boil & Spin
Method
Sixty microliters of heparin-treated whole blood was mixed with
60ml of extraction buffer (400 mM NaCl, 40 mM Tris pH 6·5,
0·4% SDS) by vortexing for 10 seconds. The suspension was then
incubated in a heating block at 95°C for 5 minutes and
centrifuged for 3 minutes at 10,000g. After centrifugation,
30mL of clear supernatant containing DNA extracted by boil &
spin (WB-B&S) was transferred to a dilution tube containing
345mL of PCR grade water.
qPCR
qPCR was performed with template DNA extracted by QIAGEN
extraction method from whole blood and DBS, using a protocol
described elsewhere, targeting the conserved REPL repeats of the
Leishmania genome (Hossain et al., 2017). Briefly, 5µL template
DNA, 10 µL of TaqMan® Gene Expression Master Mix (Applied
Biosystems), 1 µL pre-ordered Taqman primer-probe mix
(Applied Biosystems), and PCR grade water were used to
prepare 20 µL reaction mix. A Bio-Rad CFX96 iCycler system
was utilized for amplification. The conditions for amplification
were as follow- 10 min at 95°C, followed by 15 seconds at 95°C
and 1 min at 60°C (45 cycles). A standard curve was generated in
each run with 10 ng to 1 fg of parasite DNA extracted from in
vitro cultured promastigotes (L. donovani MHOM/IN/80/DD8)
corresponding to 10,000 to 0.1 parasites per reaction. One
reaction with molecular grade water as a negative control in
each assay. Samples with cycle threshold (Ct) > 40 were
considered negative. Samples were analyzed in duplicate and
for the case of an indeterminate result, an additional run
was performed.
Loopamp Assay
The Loopamp assay (Loopamp™ Leishmania Detection Kit,
Eiken Chemical Co. Ltd, Japan) was performed according to
the manufacturer’s instructions using template DNA from whole
blood prepared by QIAGEN and B&S extraction methods, and
DBS DNA extracted by QIAGEN extraction method. Template
DNA (3mL) extracted by the QIAGENmethod was added to each
tube, supplied as a string of 8 tubes with lyophilized Master Mix
in the tube caps. The volume was made up to 30mL by the
addition of 27mL Loopamp buffer. For the template DNA
prepared by B&S method, 3 mL template DNA was used
directly. Each run used one positive control and 30mL LAMP
buffer as a negative control. After the addition of the template,
tubes were closed, the string was turned upside down and shakenApril 2021 | Volume 11 | Article 670759
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minutes for reconstitution of the dried Master Mix. Following
reconstitution, the solution was spun down to the bottom of the
tubes and the string was incubated in the Loopamp™ LF-160
incubator (Eiken Chemical Co. Ltd) at 65°C for 40 minutes, then
80°C for 5 minutes. After thermal incubation, the tube string was
placed in the fluorescent unit, and samples that illuminated under
blue LED light were considered positive. The results were read by
two independent interpreters. Discordance in interpretation was
resolved by the assessment of a third interpreter.
Quality and Concentration of Extracted
DNA
The quality and concentration of the QIAGEN and B&S
extracted DNA from different samples were assessed with
Thermo Scientific Nanodrop™ 2000 Spectrophotometer
(Thermo Scientific, Hilden, Germany). DNA concentration
was determined from the OD value at 260 nm and the quality
was assessed by the ratio of OD values at 260nm and 280nm,
considering the ratio of good quality DNA ranges between 1·8-
2·0, following the standard protocol (Desjardins and
Conklin, 2010).
Leishmania Antigen ELISA
The Leishmania antigen ELISA was performed with urine samples
according to the manufacturer’s instructions (CLIN-TECH, UK).
Briefly, samples were diluted 400X for VL and 20X for controls
with assay diluent and 100mL added in duplicate to flat-bottom 96-
well microtiter plates pre-coated with sheep anti-leishmanial
antibodies (CLIN-TECH, UK). Six antigen calibrators from 0 to
50 urinary antigen unit (UAU)/mL were added to each plate in
duplicate to generate a standard curve. The plate was incubated for
30 minutes at 37°C. Following four washes, 100mL of working
strength Tracer (sheep anti-Leishmania antibody labeled with
peroxidase) was added into each well and incubated for 30
minutes at 37°C. After another wash sequel, 100mL TMB
substrate solution was added to each well and the plate was
incubated for 30 minutes at room temperature and the reaction
was stopped with the addition of 100mL stop solution (0·5M HCl).
Optical density (OD) wasmeasured at 450nm and 620nm (ELx808,
Biotek) within 30 minutes of the addition of stop solution. A four
parametric logistic curve was constructed from all of the VL antigen
calibrator points using Gen 5 software. The assay was considered
effective when the OD for the 50 UAU/mL standard was more than
1·5 and the OD for the 0 UAU/mL calibrator was less than 0·1. The
concentrations of the samples were adjusted by correcting for the
dilution factor. A receiver operating characteristic (ROC) curve was
generated to set the cut-off concentration for positivity
(supplementary information). Samples with concentration <3·11
UAU/mL were considered negative.
Statistical Analysis
Clinical sensitivity and specificity of the assays were measured
against VL case definition according to the national guideline as
a gold standard. Sensitivity and specificity [with 95% confidence
interval (CI)] were calculated using exact binomial methods forFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4proportions. McNemar’s test was performed to evaluate
discordance between the clinical evaluation and the assays. To
evaluate the inter-assay discordance McNemar’s test and
Cochran’s Q test were performed. A two-tailed paired t-test
was performed to measure differences between the means of
quantitative variables. A p-value < 0.05 was considered to
indicate statistically significant differences. The relationship
between the parasite loads detected by qPCR between WB and
DBS variables was determined by the Pearson correlation
coefficient. To measure the inter-assay agreement, the Cohen’s
kappa statistic (k) was performed. The values of Cohen’s k
coefficients were interpreted according to Landis and Koch:
1·00–0·81: excellent; 0·80–0·61: good; 0·60–0·41: moderate;
0·40–0·21: weak; and 0·20–0·00: negligible agreement (19). All
statistical analyses were performed in SPSS 20 and Graphpad
Prism 8·0.RESULTS
Patient Demographics
The clinical and demographic details of study participants are
detailed in Table 1. All patients responded well to the treatment,
were cured clinically by 6 months and none reported VL
associated clinical complications in 12 months ’ time
after treatment.
Sensitivity, Specificity, and Comparative
Analysis of the Assays
We evaluated an established qPCR assay, previously evaluated
with buffy coat DNA, with WB and DBS samples. For the qPCR
assay, the sensitivity of WB DNA extracted by QIAGEN
extraction method was 93·8% (95% CI 86·01-97·94), whereas
DBS DNA extracted by QIAGEN extraction method achieved a
sensitivity of 72·5% (95% CI 61·38-81·90). The highest sensitivity
by the Loopamp assay was achieved with WB-DNA extracted by
boil & spin method at 96·2% (95% CI 89·43-99·22), followed by
WB-DNA and DBS-DNA extracted by QIAGEN methods,
achieving 95% (95% CI 87·69-98·62) and 85% (95% CI 75·26-
92·00) sensitivity, respectively. Both the assays achieved 100%
specificity with every extraction method. Likewise, the
Leishmania antigen ELISA achieved a 97·5% (95% CI 91·47-
99·70) sensitivity that was highest among all the assays and a
specificity of 91·9% (95% CI 84·12-96·70). There were no
statistically significant differences in performance of qPCR-
WB-QIA, Loopamp-WB-QIA, Loopamp-WB-B&S and
Leishmania antigen ELISA to the clinical diagnosis of VL
according to the national guideline, as determined by exact
McNemar test (Table 2).
No statistically significant difference was found in the overall
sensitivities of the Loopamp and qPCR assays with whole blood
samples. With DBS samples, sensitivity of Loopamp was
significantly higher than qPCR. However, sensitivities of both
Loopamp and qPCR were higher with whole blood than DBS
samples. There were no statistically significant differences
between the sensitivities of Loopamp/qPCR with whole bloodApril 2021 | Volume 11 | Article 670759
TABLE 1 | Clinical and demographic details of study participants.
VL cases (n=80) Endemic healthy control (n=80)
Sex Male 47 (58·8%) 46 (57·5%)
Female 33 (41·2%) 34 (42·5%)
Age 5-11 years 17 (21·3%) 17 (21·3%)
12-17 years 05 (6·3%) 03 (3·8%)
18 ≥ years 58 (72·5%) 60 (75%)
Positive in rK39 RDT 80 (100%) 0 (0%)
Fever more than two weeks 80 (100%) 0 (0%)
Loss of appetite 50 (62·5%) 0 (0%)
Decreased body weight 25 (31·3%) 0 (0%)
Darkening of the skin 05 (6·3%) 0 (0%)
Bleeding from nose 02 (2·5%) 0 (0%)
Abdominal pain 16 (20%) 0 (0%)
Abdominal enlargement 17 (21·3%) 0 (0%)
Weakness 41 (51·2%) 0 (0%)
Pallor 58 (72·5%) 0 (0%)
Jaundice 06 (7·5%) 0 (0%)
Hepatomegaly 28 (35%) 0 (0%)
Splenomegaly 80 (100%) 0 (0%)
TABLE 2 | Sensitivity and specificity of different assays along with P values in the McNemar test.
Assay Sample type Sensitivity (n/N)* (95% CI) Specificity (n/N)¥ (95% CI) p-value in Mc Nemar test






























*Number of positives out of the 80 true VL cases.
¥Number of positives out of the 80 endemic healthy controls.
Hossain et al. Diagnostics for VL Post-Elimination Eraand the urinary Leishmania antigen ELISA, however, the
molecular assays performed significantly better in terms of
specificity than the antigen ELISA (Table 3). The agreement
between assays is shown in Figure 1.
Effect of Extraction and Sampling Methods
on Molecular Assays
The parasite burden estimated by qPCR varied considerably
between WB-QIA and DBS-QIA samples (Figure 2). In 77·5%TABLE 3 | Comparison of different assays and samples on overall diagnostic performa
Sample type Assays p-value
(cases)
Whole blood qPCR-QIA X Loopamp-QIA X Loopamp-B&Sa 0·607
DBS qPCR-QIA X Loopampb-QIA 0·002
Whole blood X DBS qPCR-QIA X Loopamp-QIA X Loopamp-B&SX
qPCR-QIA X Loopamp-QIAa
0·000
Whole blood X Urine qPCR-QIA X Loopamp-QIA X Loopamp-B&S X
Antigen ELISAa
0·392
aCochran’s Q Test, bMcNemar Test, N/A, Not analyzed due to constant values.
**p-value < 0·01, ***p-value < 0·001.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5(62/80) of the VL cases, the parasite load was greater in WB-QIA
samples. An increased parasite load was observed in 22·5% of VL
cases (18/80) by DBS-QIA method. However, a significant
correlation was found in parasite load detected by qPCR
between the two methods (r=0·723, p<0·001).
Significant variations in the mean DNA concentrations were
observed for different sampling and DNA extraction methods
when paired sample t-tests were performed (Figure 3). However,





N/A DBS: Loopamp-QIA**> qPCR-QIA
N/A WB: qPCR-QIA/Loopamp-QIA/Loopamp-B&S***> DBS:
Loopamp-QIA**> DBS: qPCR-QIA
0·000 WB: qPCR-Q/Loopamp-Q/Loopamp-B&S***> Urine: Antigen
ELISA
April 2021 | Volume 11 | Article 670759
Hossain et al. Diagnostics for VL Post-Elimination Erawere 1·829, 1·613 and 1·372 for WB-QIA, WB-B&S and DBS-
QIA methods, respectively. The highest quality DNA was
achieved by QIAGEN extraction method from whole blood,
whereas WB-B&S and DBS-QIA the quality of the DNA was
compromised by the presence of impurities.
Leishmania Antigen Concentration as a
Marker of Treatment Outcome
Significant difference was observed in the mean antigen
concentrations between the VL and control groups by
Leishmania antigen ELISA (Figure 4A). The Leishmania
antigen ELISA was also efficient in assessing treatment
outcome. Of the 41 patients who provided samples post-
treatment, 35 were antigen negative at day 30 and all patients
were antigen negative at day 180 (Figure 4B).
Comparative Assessment of the Assay
Characteristic
The features of individual assays are summarized in Table 4. The
time to result is inclusive of the time for sample processing and
the kit cost includes only the reagent cost for sample processing
(extraction etc.) and amplification.DISCUSSION
Here, we performed the Loopamp assay with whole blood and
DBS sampling with QIAGEN and B&S nucleic acid extraction
methods and compared it with a reference qPCR assay under
similar conditions, to determine the most appropriate
combination of sampling-extraction-detection for clinical
diagnosis of VL. The qPCR assay was assessed previously with
buffy coat DNA from VL patients with promising efficacyFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6(Hossain et al., 2017). However, detection of the parasite in the
peripheral blood sample is preferred over buffy coat, as only
200µL instead of 1·5mL whole blood is required to prepare the
same volume of template DNA. Besides, though the purity is low,
the B&S method is faster and retains a sufficient concentration of
template DNA (Barbosa et al., 2016).
In this study, the Loopamp-WB(B&S) achieved the greatest
sensitivity (96·2%) among the molecular assays. The higher
sensitivity of the Loopamp-WB(B&S) is attributed to the
highest template DNA recovery, though the overall purity of
the DNA is reduced relative to other extraction methods. In
another study performed in Sudan, Loopamp-WB(B&S)
achieved 97·6% sensitivity that is comparable to the present
study, with the sensitivity of Loopamp-WB(QIA) was 100%
compared to 95% sensitivity achieved here (Mukhtar et al.,
2018). However, the qPCR assays showed lower sensitivities
than the previous study with buffy coat-DNA (100%),
suggesting the qPCR assay is more effective when performed
with the buffy coat (Hossain et al., 2017).
The Loopamp assay showed higher sensitivity than qPCR in
all combinations of sampling-extraction methods. The results
varied from another study where a qPCR-WB(QIA) assay was
more sensitive (96·1%) than the Loopamp-WB(QIA) (92·3%).
However, the study incorporated qPCR targeting the kDNA and
turbidity based LAMP product detection system, compared to
the REPL repeat targeted qPCR assay and fluorimetric LAMP
product detection in the present study (Adams et al., 2018).
Moreover, the Loopamp assay offers high analytical sensitivity
(10-3 parasite equivalents/reaction) and targets two different
regions (18SrRNA gene and kDNA minicircles) (Adams et al.,
2018; Ibarra-Meneses et al., 2018), whereas the analytical
sensitivity of the qPCR is 10-1 parasite equivalent/reaction and
a single target (Hossain et al., 2017). However, the efficacies of all
three molecular assays with whole blood (Loopamp-B&S,FIGURE 1 | Inter-rater agreement observed between the assays presented as Cohen’s Kappa coefficients. The values of Cohen’s k coefficients are interpreted as:
1·00–0·81: excellent; 0·80–0·61: good; 0·60–0·41: moderate; 0·40–0·21: weak; and 0·20–0·00: negligible agreement.April 2021 | Volume 11 | Article 670759
Hossain et al. Diagnostics for VL Post-Elimination EraLoopamp-QIA and qPCR-QIA) were statistically similar and
both the Loopamp-WB(B&S) and Loopamp-WB(QIA) satisfy
the required sensitivity and specificity (≥95% and ≥98%
respectively) of an ideal diagnostic assay for VL case detection
(Boelaert et al., 2007). The qPCR-WB(B&S) assay was found
ineffective in our study (data are not shown), indicating
interference by impurities (e.g., hemoglobin, protein antibodies
etc), in agreement with previous studies (Sriworarat et al., 2015).
Use of a DBS from capillary blood collected by finger-prick
would further reduce the invasiveness of sampling, eliminate the
need for cold-chain during transportation, and would be
appropriate for mass sample collection during surveillance.
PCR experiments with DBS previously reported variable
sensitivities (70% and 90%) (Sundar and Singh, 2019).
However, to our knowledge, this is the first study evaluating
DBS samples in both qPCR and Loopamp assays for L.donovani
detection. In our study, the Loopamp-DBS(QIA) and qPCR-DBS
(QIA) assays were moderately sensitive, and the Loopamp assayFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7yielded better results than qPCR. These lower sensitivities in
qPCR and Loopamp assay with DBS samples is also documented
for conventional PCR (Smit et al., 2014) and infers inadequate
template availability, as substantiated with the observed loss in
template DNA recovery and reduced parasite load in DBS
samples. Moreover, both Loopamp-DBS(B&S) and qPCR-DBS
(B&S) assays were unable to detect parasite DNA (data not
shown), depicting the necessity of additional processing and
purification steps for the B&S method.
Integration of a test of cure and treatment monitoring,
potentially based on an antigen-based, non-invasive diagnosis
will benefit the post-elimination program. VL accompanies renal
dysfunction and associated nephropathy, resulting in the excretion
of the parasite antigens in the urine (Bezerra et al., 2019).
Therefore, detection of the Leishmania antigens in urine for VL
diagnosis is a promising non-invasive diagnostic approach to
support the post-elimination program. We investigated one such
prospective urine-based detection system, the Leishmania antigenFIGURE 2 | Differences in the parasite burden by qPCR between whole blood and DBS DNA extracted by QIAGEN method. (A) The mean parasite load in WB-QIA
was 1,818 parasite/mL WB (SD=3,740 parasite/mL) and DBS-QIA was 899 parasite/mL WB (SD=2,069 parasite/mL). In a paired sample t-test, significant differences
were observed in the mean parasite load between the two sample categories with t (79) =3·092, P=0·0027. (B) Trend in parasite load between the two sampling
methods. Each point indicates the data obtained from an individual sample. The connecting line links data for each patient in WB-QIA and DBS-QIA method.FIGURE 3 | Concentration of DNA extracted by QIAGEN and boil & spin methods from whole blood and DBS samples(n=72). The mean DNA concentration was
highest for WB-B&S, 27·51 ng/µL (SD=9·45 ng/µL), followed by WB-QIA and DBS-QIA, 18·68 ng/µL (SD=12·10 ng/µL) and 8·09 ng/µL (SD=15·47 ng/µL)
respectively. In a two-tailed paired t-test, significant differences in the mean concentrations were observed for WB-QIA and WB-B&S (t(71)=4·981, P<0·0000),
WB-B&S and DBS-QIA (t(71)=8·978, P<0·0000) and WB-Q and DBS-Q (t(71)=4·398, P<0·0000).April 2021 | Volume 11 | Article 670759
Hossain et al. Diagnostics for VL Post-Elimination EraELISA. It is a quantitative, capture ELISA exploiting anti-
Leishmania poly-clonal antibodies produced against whole
promastigotes to detect Leishmania antigens excreted in urine
(Vallur et al., 2015). The sensitivity in this study was 97·5% with
significant differences in antigen concentration between the case
and controls. However, the specificity in the endemic controls was
moderate, consistent with our previous study (90%), however, we
set our cut-off concentration from receiver operating characteristic
(ROC) curve to adjust the precision (Vallur et al., 2015). The assay
performance was statistically inferior in terms of specificity when
tested against the molecular assays of similar sensitivities.
However, the assay was accurate in conferring complete clinical
cure at day 180, in agreement with the definition of clinically cured
cases according to the current national guideline, (NKEP, CDC ,
2016) and further assured by no reported clinical complications
related to VL in a one-year follow up period. The results are
consistent with a previous study in Ethiopian subjects with similar
accuracy to determine clinical cure (Vallur et al., 2015).
Attaining the VL elimination status will subsequently limit
funding and programmatic activities are likely to be committed
to the public healthcare system. Therefore, apart from the
efficacy, the aptness of the assays for the post-elimination
setting hinges upon other parameters e.g., cost, feasibility,
scalability, and robustness. Reckoning the efficacy, feasibility,
and cost, the Loopamp assay succeeded the qPCR assay in our
study and emerged as a promising alternative (Table 4).
Lyophilized reagents, one step-single tube LAMP assay,
compact device, and visual detection of the LAMP products
with the in-built fluorescence unit of the Loopamp™ LF-160
incubator made the assay apt for peripheral health care setting
(Besuschio et al., 2017; Adams et al., 2018). Coupling the B&S
extraction with the Loopamp assay further lessened the time and
cost along with a simplified protocol that increased the assay
feasibility. The assay is also minimally invasive and requires only
60µL of blood as an initial sample which is equivalent to 2 drops
of peripheral blood. The sampling feasibility can be therefore
increased utilizing finger-pricked blood and requires
investigation. Additionally, the availability of the Loopamp TB
(WHO recommended) and Malaria detection kit increases itsFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8prospect to be exploited as an integrated diagnostic platform
along with VL (World Malaria Report, 2019, Geneva).
The limitations of the Loopamp assay comprise its limited
throughput and absence of the quantification feature compared to
the qPCR. Also, utilization of FTA cards in DBS-Loopamp
increased the assay cost (Table 4), rendering the assay less
desirable for mass screening during post-elimination
surveillance. The Leishmania antigen ELISA in contrast is more
compatible for surveillance studies as another sensitive, cost-
effective, high-throughput, and non-invasive diagnostic tool,
offering sampling feasibility and increased patient compliance
(Abeijon and Campos-Neto, 2013). The prospect of the assay to
identify asymptomatic carriers from a cohort is explored in a
recent study with promising outcome (Owen et al., 2021). Its
unique quantification feature can also be exploited to determine
treatment outcome. However, the low specificity may cause
inconclusive results, requiring a secondary test for confirmation.
For basic laboratory research requiring precise quantification of
parasites, e.g., evaluation of novel vaccines, drugs, and diagnostic
innovations etc., however, the qPCR assay is preferred.
Defining elimination by prevalence instead of the
transmission status is a caveat in the elimination strategy and
the continuous transmission, as evidenced by increased non-
endemic VL cases, is impeding the validation process (Olliaro
et al., 2017; Cloots et al., 2020). Therefore, in light of other
neglected tropical disease (NTD) elimination programs (e.g.
filariasis and schistosomiasis), the VL endgame policies should
consider the interruption of transmission as the basis of infection
containment in the post-elimination era (Stothard et al., 2017;
Fang and Zhang, 2019). Effective interruption of VL
transmission can only be achieved by reducing the
transmission window of the infection via early diagnosis.
Therefore, the VL patients according to the national guidelines
that is the presence of clinical symptoms for two weeks along
with rK39 positivity (NKEP, CDC, 2016). The enrollment was
completed at SKKRC which is a referral center for VL, and the
suspects were primarily diagnosed elsewhere. Therefore, all the
suspects were clinically advanced and rK39 RDT positive during
enrollment. As such, the efficacies of the assays for VL detectionFIGURE 4 | (A) Differences in the concentration of urinary antigen between VL and endemic control groups at baseline. The mean Ag concentration in the VL group
was 1,706 UAU/mL (SD=3,106 UAU/mL) and the mean Ag concentration for controls was 0·8523 UAU/mL (SD=1·507 UAU/mL). Significant differences were
observed by two-tailed t-test between the two groups (t (79) = 4·912, P<0·0001). (B) Concentration of urinary Ag in VL patients at baseline, 30 days after treatment
and 180 days after treatment (n=41). The mean Ag concentration at baseline was 1,681 UAU/mL (SD=2,888 UAU/mL), 10·94 UAU/mL (SD=42·36 UAU/mL) at day
30 after treatment and 0·0585 UAU/mL (SD=0·375 UAU/mL) at day 180 after treatment.April 2021 | Volume 11 | Article 670759
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investigation is required with stratified time points since the
onset of the symptoms. The microscopic detection of parasites in
splenic aspirate was initially included as a diagnostic gold
standard for VL in the study protocol. However, the procedure
was discontinued in the early phases of the study following a
serious adverse event reported. Also, the performance of the
Loopamp assay as a test-of-cure was not evaluated and the
efficacies of both the assays to detect treatment failures and
relapse cases requires investigation.
In absence of definite tools to measure VL transmission,
identification of the infectious pockets via epidemiological
surveillance and ensuring early diagnosis are the only reliable
measures to contain transmission in the post-elimination setting.
Our study presented the Loopamp™ Leishmania Detection Kit
with B&S extracted whole blood DNA and the Leishmania
antigen ELISA promising to facilitate such post elimination
diagnosis and epidemiological surveillances, respectively. A
phase-3 diagnostic trial is therefore recommended in the
peripheral settings to integrate the assays into the post-
elimination VL control strategies.DATA AVAILABILITY STATEMENT
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Sample preparation Manual Manual Manual Manual Manual Manual
Automation for detection
and analysis
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Detection of L. donovani markers Direct Direct Direct Direct Direct Direct
Mode of sample collection Invasive Invasive Invasive Invasive Invasive Non-invasive
Volume of sample required 200uL
peripheral blood







Samples analyzed per assay 82 82 14 14 14 82
Time to result/assay 2:45 hours 3 hours 1:20 hour 1 hour 2:40 hours 2 hours
Kit cost/reaction ~16·5 USD ~18·9 USD ~10·12 USD ~6·92 USD ~12 USD ~6·12 USD






















Storage temperature of reagents -20°C -20°C Room temperature Room temperature Room temperature 4°C
Health care setting Tertiary Tertiary Point-of-care Point-of-care Point-of-care Secondary/
TertiaryApril 2021 | Volume 11 | Article 670759
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Supplementary Figure 1 | Receiver operating characteristic (ROC) curve for
Leishmania Antigen ELISA for determination of the cut-off Urinary antigen unit (UAU)
for the detection of Leishmania antigens in urine samples. From the ROC curve, the
selected combination of the sensitivity and specificity was 97.50% and 91.25%
which gave a cut-off of >3.11 UAU.
Supplementary Figure 2 | Study activity flow diagram.
Supplementary Figure 3 | Standards for Reporting of Diagnostic Accuracy
(STARD) flow diagram. (A) Sample flow and test results for cases. (B) Sample flow
and test results for controls.REFERENCES
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